Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates
March 28, 2024 07:00 ET
|
Galera Therapeutics
MALVERN, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have...
Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
November 14, 2023 07:00 ET
|
Galera Therapeutics
FDA confirms need for new trial for avasopasem; GRECO trials with rucosopasem to be discontinued Company evaluating potential strategic options to optimize shareholder value MALVERN, Pa., Nov. 14,...
Galera Announces Receipt of Type A Meeting Minutes and Strategic Update
October 31, 2023 07:00 ET
|
Galera Therapeutics
FDA confirms need for new trial for avasopasem for severe oral mucositis (SOM) GRECO-2 trial did not pass futility analysis; Company will discontinue both GRECO trials Company reviewing potential...
Galera Schedules Type A Meeting with FDA to Discuss Next Steps for Avasopasem
September 18, 2023 07:00 ET
|
Galera Therapeutics
MALVERN, Pa., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023 07:00 ET
|
Galera Therapeutics
MALVERN, Pa., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
August 14, 2023 07:00 ET
|
Galera Therapeutics
Company received Complete Response Letter from FDA for avasopasem and intends to request Type A meeting with FDA to discuss potential next steps Cash runway extended into Q2 2024 in connection with...
Galera Receives Complete Response Letter from U.S. FDA for Avasopasem Manganese
August 09, 2023 16:31 ET
|
Galera Therapeutics
The Company remains committed to its goal of bringing avasopasem to patients and intends to meet with FDA as soon as possible to discuss potential next steps Galera will take actions to extend its...
Galera Presents Additional Chronic Kidney Disease Data from ROMAN Trial at 2023 ASCO Annual Meeting
June 05, 2023 14:15 ET
|
Galera Therapeutics
As previously reported, avasopasem reduced cisplatin-related chronic kidney disease by 50% compared to placebo at one-year follow-up Additional data demonstrated improved preservation of kidney...
Galera Announces FDA Orphan Drug Designation Granted to Rucosopasem for Pancreatic Cancer
May 18, 2023 08:00 ET
|
Galera Therapeutics
MALVERN, Pa., May 18, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera Reports First Quarter 2023 Financial Results and Recent Corporate Updates
May 11, 2023 07:00 ET
|
Galera Therapeutics
Avasopasem NDA granted FDA priority review for radiotherapy-induced severe oral mucositis (SOM); PDUFA target date of August 9, 2023 Company raised $30 million in gross proceeds from registered...